Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$173.04 USD

173.04
1,581,725

-0.88 (-0.51%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib

AbbVie (ABBV) submits regulatory applications in the United States and EU for upadacitinib, for the treatment of adult patients with moderate to severe rheumatoid arthritis.

Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug

Alkermes (ALKS) and Biogen submit an NDA to the FDA for diroximel fumarate (BIIB098), being developed for the treatment of relapsing forms of MS.

Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU

Roche's (RHHBY) investigational oral medicine risdiplam gets PRIME designation for the treatment of SMA.

Sweta Killa headshot

5 Incredible ETFs & Stocks to Buy on the Dip

The dips might charge up investors to snap up stocks and ETFs on the cheap for outsized gains heading into Christmas.

5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019

The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.

The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate

A low key week for the biotech sector with focus on regular pipeline updates.

The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

Ekta Bagri headshot

4 Biotech Stocks Investors Can Add to Their Portfolio in 2019

Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.

Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis

Biogen (BIIB) obtains a license to develop and commercialize BIIB067 from Ionis Pharmaceuticals. The candidate is being developed for treatment of ALS with SOD1 mutations.

FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101

The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.

AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018

AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH) annual meeting.

Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma

Teva (TEVA) and partner Celltrion get FDA nod for approval of their biosimilar to Roche's Rituxan in three Non-Hodgkin's lymphoma indications.

Why Is Biogen (BIIB) Up 4.5% Since Last Earnings Report?

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up

PDL BioPharma's (PDLI) earnings trump estimates in Q3. Higher royalties and product sales aid a significant surge in year-over-year revenues.

Tirthankar Chakraborty headshot

5 Top Stocks to Make the Most of a Divided Congress

Gridlock in Washington bodes well for healthcare and defense stocks, which calls for investing in such a space for the time being.

Tirthankar Chakraborty headshot

Election Day 2018: Here Are the Winners & Losers

One of the most awaited midterm elections in American history is upon us. Let's thus look at the sectors most likely to be impacted by the election results.

Biotech ETFs in Focus on String of Q3 Earnings Beat

Biotech ETFs draw attention post impressive Q3 results.

What's in the Cards for AbbVie (ABBV) This Earnings Season?

Impressive sales of AbbVie's (ABBV) key drugs, Humira, Imbruvica and Mavyret are expected to drive third-quarter sales.

Mark Vickery headshot

Top Research Reports for McDonald's, Thermo Fisher & Caterpillar

Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), Thermo Fisher (TMO) and Caterpillar (CAT).

Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod

Earnings releases and key data-read outs were the key developments in the biotech sector last week.

Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG

Four drug/biotech stocks are scheduled to release their third-quarter results on Oct 25. Let???s take a look at how these companies are poised ahead of their earnings release.

Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook

Alkermes (ALKS) surpasses earnings and sales expectations in the third quarter of 2018 and raises its financial guidance for 2018.

Biogen (BIIB) Q3 Earnings & Sales Beat, Spinraza Shines

Biogen beat estimates for both earnings and sales in the third quarter. Its newest drug Spinraza performs well in the quarter.